CJC-1295: Benefits, Side Effects & DAC vs No DAC

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone, a signal that stimulates growth hormone release. The long-acting form studied in humans increased growth hormone and IGF-I, a hormone involved in growth signalling.

DAC, No DAC and CJC-1295–Ipamorelin combinations are different preparations. Here is what researchers measured and which findings apply to which material.

Sources checked: 22 October 2026.

What benefits and results did human studies find?

In two short placebo-controlled trials, long-acting CJC-1295 increased mean growth hormone by 2–10 times for at least six days and IGF-I by 1.5–3 times for 9–11 days after a single injection. The estimated half-life was 5.8–8.1 days. Teichman and colleagues, 2006 studied healthy adults aged 21–61 over 28 and 49 days.

Question	Study finding	What it tells us
Does it increase growth hormone?	Mean GH increased 2–10-fold.	A measured hormonal response to long-acting CJC-1295.
Does it increase IGF-I?	Mean IGF-I increased 1.5–3-fold.	A measured response, not a prediction of muscle gain.
Does it improve muscle gain, fat loss, sleep or recovery?	Those outcomes were not established by these trials.	Hormone changes alone do not quantify these benefits.

What is the difference between DAC and No DAC?

DAC means Drug Affinity Complex. The long-acting preparation binds to albumin, a blood protein, which prolongs its activity. Its multi-day half-life must not be assigned to material sold as No DAC.

The distinction is not simply “continuous versus natural pulses.” A human study of long-acting CJC-1295 found that growth-hormone pulsatility was preserved. Compare the actual preparation rather than that marketing shorthand.

CJC-1295 versus Ipamorelin: are they the same?

No. CJC-1295 is a GHRH analogue; Ipamorelin is a separate growth-hormone secretagogue. Research on either ingredient alone does not establish the results of a combined vial. See the original Ipamorelin pharmacology paper.

Compare the ingredients and their stated quantities before comparing products. Read Ipamorelin versus CJC-1295 or check the CJC-1295 + Ipamorelin product specification.

What side effects have been reported?

FDA reviews describe increased heart rate and systemic vasodilatory reactions associated with CJC-1295. Reported reactions also include flushing, headache, nausea and dizziness. See the FDA clinical review.

The short published trial reported no serious adverse reactions within that study. That does not erase reports from other settings or establish long-term safety.

What about CJC-1295 dosage?

A 5 mg vial states the mass of material, not a clinical regimen. The studies discussed here examined long-acting CJC-1295 under controlled conditions; they do not establish a No DAC–Ipamorelin regimen for muscle gain or fat loss.

Concentration is a separate calculation: material mass divided by liquid volume. The peptide reconstitution calculator and formulas show that arithmetic; they cannot determine an appropriate treatment. For mixtures, use the blend calculation worksheet with the stated amount of each ingredient.

Which CJC-1295 material does PP list?

PP lists CJC-1295 (No DAC) 5 mg and a separate CJC-1295 + Ipamorelin blend. The 5 mg figure is the declared material mass, not concentration in mg/mL.

No independent CJC-1295 (No DAC) report is currently published in the PP report register. A purity target is not a measured result for an untested product.

PP supplies laboratory research material only, not products for human or veterinary use.